Cerebral small vessel disease (CSVD) is a common group of neurological conditions that confer a significant burden of morbidity and mortality worldwide. In most cases, CSVD is only recognized in its advanced stages once its symptomatic sequelae develop. However, its significance in asymptomatic healthy populations remains poorly defined. In population-based studies of presumed healthy elderly individuals, CSVD neuroimaging markers including white matter hyperintensities, lacunes, cerebral microbleeds, enlarged perivascular spaces, cortical superficial siderosis, and cerebral microinfarcts are frequently detected. While the presence of these imaging markers may reflect unique mechanisms at play, there are likely shared pathways underlying CSVD. Herein, we aim to assess the etiology and significance of these individual biomarkers by focusing in asymptomatic populations at an epidemiological level. By primarily examining population-based studies, we explore the risk factors that are involved in the formation and progression of these biomarkers. Through a critical semi-systematic review, we aim to characterize “asymptomatic” CSVD, review screening modalities, and draw associations from observational studies in clinical populations. Lastly, we highlight areas of research (including therapeutic approaches) in which further investigation is needed to better understand asymptomatic CSVD.

Keywords Cerebral small vessel diseases; Epidemiology; Stroke, lacunar; Leukoaraiosis

Introduction

Several of the recent developments in stroke care have focused on the treatment of large vessel occlusions and pathologies. However, there have been few advancements in the management of cerebral small vessel disease (CSVD) largely because small vessels are difficult to observe radiographically and their underlying pathogenic mechanisms are incompletely understood. This is problematic given that CSVD contributes to a number of clinically relevant sequelae including hemorrhagic stroke, vascular cognitive impairment (VCI), gait disturbances including parkinsonism, bladder dysfunction, and epilepsy. Furthermore, a large proportion of ischemic stroke and dementia are attributed to CSVD (20% and 45%, respectively). One of the greatest challenges is that there are limited means to assess CSVD prior to the development of its clinical sequelae. Moreover, even after identification of CSVD in healthy populations, management of this disease is not well established. In
this review, we aim to summarize basic definitions of CSVD and CSVD biomarkers, highlight our current understanding of CSVD as it relates to "healthy" populations, and where relevant, incorporate evidence from observational studies in different clinical populations. We will focus on asymptomatic CSVD, defined as neuroimaging evidence of CSVD prior to the development of any overt clinical symptoms. Although we will review the major population-based studies in the field, we will cross-link our findings with those of clinical cohorts to unravel clinical relevance and put data into perspective. The emphasis of this paper will be sporadic non-amyloid CSVD (often termed "hypertensive arteriopathy"), as there are several recent reviews that discuss monogenetic CSVD and cerebral amyloid angiopathy (CAA)-related CSVD.15-18

Methods

Search strategy and selection criteria
Articles from January 1951 to July 2018 were identified through searching the PubMed (National Center for Biotechnology Information, National Library of Medicine) database. The following title/abstract search terms were employed: "cerebral small vessel disease AND population," "silent lacunar infarcts AND population," "white matter hyperintensities AND population," "cerebral microbleeds AND population," "perivascular spaces AND population," "cortical superficial siderosis AND population," and "cerebral microinfarcts AND population." Exclusion terms were not used in the search criteria. Searches were limited to full-text articles available in English. Additional references were selected by reviewing the reference lists of relevant publications. As this review was restricted to asymptomatic disease, most articles discussing symptomatic stroke or intracerebral hemorrhage (ICH) were excluded. Furthermore, we excluded literature pertaining to CAA given that our focus was on sporadic, non-amyloid CSVD.

Data analysis

By using the above search methodology, 642 articles were generated. Articles were independently screened by two authors (A.S.D. and R.W.R.) for appropriateness and relevance to the topic. Two hundred and eight articles were ultimately selected for incorporation in this review. Using this analysis, we generated a semi-systematic review.

CSVD definitions

CSVD is a broad term that incorporates both neuroimaging and neuropathological findings that pertain to smaller vessels (5 µm to 2 mm) in the gray and white matter including arterioles, capillaries, and venules.6,7,14,19 While both concepts have been raised in the literature, it should be noted that neuroimaging markers reflect CSVD, but do not define the disease in its entirety. CSVD is often diagnosed by neuroimaging features seen occasionally on computed tomography (CT), but more sensitively detected by magnetic resonance imaging (MRI). These MRI markers include white matter hyperintensities (WMHs) of presumed vascular origin, recent small subcortical infarcts and lacunes, cerebral microbleeds (CMBs), perivascular spaces (PVSs), cortical superficial siderosis (cSS), brain atrophy, and cerebral microinfarcts (CMIs) (Figure 1).2,14 In 2013, these imaging markers (with the exception of CMI) were defined by the Standards for Reporting Vascular changes on nEuroimaging (STRIVE) consortium, which unified definitions of CSVD biomarkers based on key neuroimaging characteristics.20 In most cases, not all of these neuroimaging markers will be present together in a single brain scan. Whether the presence or anatomical location of certain imaging markers reflects distinct small vessel pathways is not fully understood. While the true burden of CSVD is not known, estimates suggest that at least one-third of healthy-populations have lacunes (the majority of which are due to CSVD), although the actual prevalence of CSVD is likely much higher.21,22 While these, often called "silent strokes," are visible on CT or MRI, they por-
tend no clinical syndrome because of their small size and non-eloquent location (sparing motor cortices, cranial nerves, or language centers). However, in patients without CSVD visible on 1.5T MRI, infarcts may still be present, but visible only on ultra-high resolution (7T) MRI images or by pathologic examination. The burden of these CMI can be formidable, with estimates suggesting hundreds to thousands of infarcts in a single brain.\textsuperscript{23-25} This fact underscores the difficulty of diagnosing and ascertaining the extent of CSVD, such that the mere presence of one biomarker such as WMH can reflect a much larger process involving several pathological disruptions to the cerebral microvasculature.\textsuperscript{26}

CSVD is a dynamic process in which lesions including WMH, CMB, and lacunes can progress or regress (even after accounting for differences in MRI technique).\textsuperscript{27,28} The implications of this on CSVD is not well understood but may be a balance between small vessel arteriopathy and neural repair processes. Hypertension and other vascular risk factors are believed to be the primary culprits of this entity as we will see from several epidemiological studies. Herein, we aim to review the epidemiological studies that pertain to each of the major neuroimaging markers. We limit discussion of brain atrophy, given that it is beyond the scope of the present review.

**White matter hyperintensities of presumed vascular origin**

WMH of presumed vascular origin, often termed leukoaraiosis in early reports,\textsuperscript{29-31} are of variable size, but appear hyperintense on T2-weighted (T2) and fluid attenuated inversion recovery (FLAIR) MRI sequences and hypointense/isointense on T1-weighted sequences.\textsuperscript{20} They are more difficult to detect on CT, but may be seen as hypodensities (or hypoattenuated areas). Typically, they spare the subcortical U-fibers, and presumably are due to chronic hypoperfusion with increased blood-brain barrier permeability.\textsuperscript{31-33} although pathological reports have been infrequent and discordant.\textsuperscript{34} Mechanistic insight provided by advanced neuroimaging methods suggests that there are likely early alterations in interstitial fluid mobility that eventually lead to demyelination and axonal damage.\textsuperscript{35} Because WMH are highly prevalent in “healthy” populations (Table 1),\textsuperscript{35-44} it remains unclear whether WMH are always pathologic. However, punctate WMH are probably due to a variety of causes and have relatively low risk for further progression. On the other hand, confluent WMH are likely to progress in a more aggressive fashion.\textsuperscript{45} While not fully clear, subcortical WMH and periventricular WMH may represent the same spectrum of disease leading to devastating clinical outcomes.\textsuperscript{34,46} Because of limitations in neuroimaging techniques and MRI processing methods, differentiating WMH from other lesions or artifacts (such as corticospinal tracts or blood flow) can be difficult.\textsuperscript{34}

Several population-based studies have explored the risk factors associated with development of CSVD. The major studies include the Cardiovascular Health Study (CHS), Austrian Stroke Prevention Study (ASPS), Rotterdam Study (RS), and Atherosclerosis Risk in Communities Study (ARIC). While these studies have yielded several conflicting results, there are some patterns that have emerged. In the CHS,\textsuperscript{39,42} a longitudinal study of elderly (\geq 65 years) community-dwelling adults, approximately three-fourths of the study population exhibited periventricular

### Table 1. Major population-based studies of WMH in healthy subjects

| Population-based study                        | Year | Study size | Mean age (yr) | WMH burden (%) | WMH risk factors                                                                 | WMH progression (%) (duration, yr) | WMH progression risk factors |
|----------------------------------------------|------|------------|---------------|----------------|---------------------------------------------------------------------------------|-----------------------------------|-------------------------------|
| Cardiovascular Health Study\textsuperscript{25,26} | 1989 | 3,301      | 74            | 96             | Age, silent infarct, SBP, lower FEV\textsubscript{1}, low income                  | 28 (5)                            | Age, DBP, decreased LDL (low grade); diuretics use, statin use (high grade); cigarette smoking, baseline infarct (both) |
| Austrian Stroke Prevention Study\textsuperscript{43,44} | 2005 | 273        | 60            | 65             | NR                                                                              | 17.9 (3)                          | Baseline WMHV, DBP             |
| Rotterdam Scan Study\textsuperscript{37,38}    | 1990 | 1,077      | 72            | 95             | Age, female gender                                                              | 39 (3.4)                          | Baseline WMHV, female sex, age, BP, smoking |
| Atherosclerosis Risk in Communities Study\textsuperscript{39,42} | 1987 | 1,920      | 62            | 86             | Age, smoking, alcohol use, education, SBP, DBP, African American race            | 23 (9)                            | SBP, smoking                   |
| Framingham Offspring Cohort Study\textsuperscript{43,44} | 1948 | 1,814      | 53            | NR             | Smoking, hypertension                                                           | NR (10)                           | Smoking, BP                    |

For each population-based study, the percentage of patients with WMH is shown. The percentage of individuals with WMH progression is shown as well as the duration of study in parenthesis. Risk factors for WMH formation as well as progression are listed.

WMH, white matter hyperintensity; SBP, systolic blood pressure; FEV\textsubscript{1}, forced expiratory volume in 1 second; DBP, diastolic blood pressure; LDL, low-density lipoprotein; NR, not reported; WMHV, white matter hyperintensity volume; BP, blood pressure.
rather than subcortical WMH and about one-fifth of population had equal distributions in both regions. Higher WMH burden was associated with older age, asymptomatic stroke on MRI, higher systolic blood pressure (BP), smoking, and female gender, with age showing the strongest correlation. By contrast, the majority of WMH in the RS, a population-based-cohort study that recruited nondemented individuals ages 60 to 90 years, were found in subcortical areas and to greater extent in frontal and parietal regions. As shown in a sub-study of the RS, arterial stiffness (as measured by the aortic pulse wave velocity) was associated with larger WMH volumes independent of cardiovascular risk factors. Similar to CHS, WMH were also associated with increasing age. Regardless of age or anatomic location, women had a higher burden of white matter lesions (both in periventricular and subcortical areas) consistent with findings from the PROspective Study of Pravas- tatin in the Elderly at Risk (PROSPER) study as well as CHS. This may be due to decreased estrogen after menopause allowing the brain to be more prone to hypoxia. Interestingly, in a longitudinal sub-study of PROSPER, deep WMH progression among women was twice that of men, whereas the increase in periventricular WMH was similar. In the ARIC study, a prospective study that recruited middle-aged men and women, hypertension was associated with WMH. For unclear reasons, blacks had a lower prevalence of WMH, but a higher prevalence of severe WMH. In a follow-up study, blacks, who had a higher incidence of baseline hypertension, experienced more WMH progression than Caucasians. Unlike many of the other population-based studies (in which blacks were less represented), this finding suggests that hypertension may influence CSVD progression. However, it is uncertain whether black race is independently associated with WMH burden or whether hypertension contributes indirectly. In addition to blacks, Asians have a high burden of CSVD, although the location of their WMH is similar to that of Europeans, but more strongly associated with age. Similar to blacks, hypertension is also strongly associated with WMH burden in Asian populations.

In early longitudinal studies, baseline CSVD (lacunes and WMH) seems to have the strongest association with WMH progression, although there has been conflicting information regarding whether WMH progression occurs in periventricular or subcortical (deep) areas. In follow-up studies examining the progression of WMH in the CHS, the risk of clinical stroke was increased among patients with high baseline WMH burdens and asymptomatic strokes. Interestingly, with the exception of cigarette smoking and presence of an infarct on baseline MRI, the relationship between risk factors and WMH progression was dependent on low versus high WMH burden at initial scan (Table 1). Baseline WMH burden was also found to be important in the ASPS, a single-center population-based study that enrolled around 2,000 individuals in Graz, Austria, ages 50 to 75. In a 3-year period, subcortical WMH progression occurred in deep and subcortical areas, and was associated with diastolic BP as well as baseline WMH burden. However, in a 6-year follow-up study, only baseline WMH grade was ultimately associated with WMH progression. Similar to the ASPS, the RS showed that WMH progression occurs in subcortical areas compared to periventricular areas, a finding which was also replicated in the Leukoaraiosis And DIbility study (LADIS). Interestingly, one Japanese study of neurologically healthy adults demonstrated that subcortical WMH were more associated with increased future risk of stroke than periventricular WMH, although periventricular WMH were associated with an increased risk of death. In the RS, WMH progression was associated with a broad range of previously-identified risk factors and in young patients and in patients without severe WMH at baseline, hypertension was strongly associated with lesion progression. Interestingly, a small percentage of subjects demonstrated WMH regression in subcortical areas (and to a much lesser extent periventricular areas), highlighting the dynamic nature of CSVD.

In the Framingham Offspring study, WMH were associated with an increased risk of symptomatic stroke, dementia, amnestic cognitive impairment, and death. Similar studies have shown that WMH can modulate the progression from normal to mild cognitive impairment, with periventricular WMH playing a more critical role than deep/subcortical WMH. In the RS, apolipoprotein (APOE) ε4 carriers, which have increased rates of Alzheimer’s disease, had higher WMH burdens, especially if carriers had comorbid hypertension. This has been corroborated by other studies relating APOE to WMH burden. In the RS, 4.2% of subjects developed dementia, which was associated with a higher burden of periventricular WMH compared to subcortical WMH.

Recent small subcortical infarcts and lacunes

Because of advancements in neuroimaging that have led to improved detection of asymptomatic infarcts, the STRIVE consortium separated lacunar stroke into recent small subcortical infarct and lacune of presumed vascular origin. Lacunes likely represent the chronic end-product of small subcortical infarcts. Recent small subcortical infarcts are sometimes accompanied by clinical lacunar syndromes, as initially described by Fisher or they can be found incidentally by lesions with re-
restricted diffusion on diffusion-weighted imaging (DWI) without an accompanying clinical stroke syndrome. Small subcortical infarcts are dynamic, and over-time, can disappear, cavitate (forming lacunes), or form WMH. On imaging, small subcortical infarcts follow the territory of a perforating arteriole, are <20 mm in maximal diameter, and exclude striatocapsular infarcts and anterior choroidal infarcts (which have a different underlying etiology). They are relatively easy to detect on MRI because they appear hyperintense on DWI and hypointense on apparent diffusion coefficient images. Pathologically, they are presumably due to occlusion of small perforating arterioles through a variety of mechanisms including microatheromatous disease or cardioembolism.

Lacunes of presumed vascular origin are appropriately named given the fluid-filled cavity that is often found after a lacunar stroke. By consensus definitions, lacunes are a round or ovoid, subcortical, fluid-filled cavity between 3 and 15 mm in diameter. They follow the signal intensity of cerebrospinal fluid on all sequences and on FLAIR images, and they have a central hypointensity with a surrounding rim of hyperintensity (in contrast to PVS). Incidental small subcortical infarcts are not commonly observed at high-frequencies in studies of asymptomatic populations, and so therefore our analysis will be limited to lacunes. Given that previous analysis of lacunes have been reviewed systematically, we will highlight only the major population-based studies.

In healthy populations, the frequency of lacunes ranges from 8% to 31% (owing to differences in the ages of the study populations and variability in spatial resolution of imaging studies). Although the associated risk factors have varied between studies, hypertension, age, and (to a lesser degree) smoking, seem to be the most replicated. Conflicting associations between gender and infarct presence have been observed: in the CHS and Shunyi Study, male gender was found to be associated, and in the RS, female gender was found to be associated. Other less robust risk factors that have been shown to be associated with silent lacunes include serum creatinine, diabetes, cholesterol, homocysteine levels, and black race. Interestingly, carotid atherosclerosis was found to be associated with silent lacunes, suggesting that small subcortical infarcts can occur through artery-artery embolism or flow limiting effects.

In these studies, lacunes were typically found in the lenticular nucleus and thalamus whereas a large portion of symptomatic infarcts were found in the cerebral cortex, thereby invoking other etiologies such as internal carotid artery atherosclerosis or atrial fibrillation. Although many of these individuals did not experience any clinical symptoms of stroke, they were more likely to perform poorly on neuropsychological testing, highlighting the “covert” nature of CSVD. In longitudinal studies, the progression of lacunes occurs in 3.5% to 4.1% of subjects annually. Baseline cerebrovascular disease (WMH and lacunes) seems to be the most prominent risk factor for development of additional lacunar infarcts, which are predominantly located in subcortical regions or in the deep basal ganglia. The association between baseline WMH and infarct development suggests that there may be a common pathway underlying these two markers. Similarly, symptomatic strokes are likely to represent a lesion in the same spectrum as asymptomatic strokes. Individuals with these silent brain infarcts are twice as likely to develop symptomatic stroke, which share many of the same risk factors as silent infarcts. Of the individuals that experienced a symptomatic stroke during follow-up studies, the majority were more likely to have a silent lacunar stroke or a higher WMH burden on their initial MRI.

Cerebral microbleeds

CMBs are areas (≤10 mm) of round/oval shaped signal voids with blooming effect on MRI, best seen on T2*-weighted gradient-recalled echo (GRE) or susceptibility-weighted imaging. They are located in the cortico-subcortical junction and deep gray or white matter throughout the brain (including brainstem and cerebellum). Histopathologically, in microangiopathies that affect small penetrating vessels (such as non-CAA CSVD/hypertensive vasculopathy” or CAA), there is often extravasation of blood products into perivascular tissues leading to activation of macrophages; these foci of hemosiderin-laden macrophages are representative of microbleeds. Clinically, they are associated with ICH and stroke (especially in CAA). However, the clinical significance of CMB in healthy populations is poorly understood.

CMBs are a common finding in “healthy” populations. The prevalence of CMB ranges from 3.1% to 15.3% owing to differences in the sensitivity of MRI sequences used (Table 2). In subjects with CMB, the majority have <3 lesions located in cortico-subcortical areas. However, in non-European populations, CMB are found more predominantly in deep areas, which may be related to increased rates of hypertension although the prevalence of CMB is relatively the same. While several risk factors are associated with CMB presence, the two most consistently associated are age and hypertension. For example, in the Framingham Study Original Cohort and Offspring Cohort, the prevalence of CMB was 12.6% in patients 75 years of age or older compared to 2.2% in patients younger than 75. With improved detection sensitivity using 3D-
Table 2. Prevalence and risk factors of CMBs in healthy populations

| Population-based study         | Year | Study size | Mean age (yr) | MRI field strength (T) | Prevalence (%) | Risk factors                                      |
|--------------------------------|------|------------|---------------|------------------------|----------------|---------------------------------------------------|
| Austrian Stroke Prevention Study107 | 1999 | 280        | 60            | 1.5                    | 6.4            | Age, HTN, SSI, WMH                                 |
| Tsushima et al.105             | 2002 | 450        | 53            | 1.0                    | 3.1            | HTN and smoking                                   |
| Framingham Study104            | 2004 | 472        | 64            | 1.0                    | 4.7            | Age, male gender                                  |
| AGES-Reykjavik103              | 2008 | 1,962      | 76            | 1.5                    | 11.1           | Age, male gender, APOE ε4 status                  |
| Rotterdam Scan Study106        | 2010 | 3,979      | 60            | 1.5                    | 15.3           | SBP, HTN, smoking, SSI, WMH                      |
| RUN-DMC112                     | 2011 | 485        | 66            | 1.5                    | 10.7           | NR                                               |
| Atahualpa Project111           | 2015 | 258        | 70            | 1.5                    | 11.0           | WMH, SSI, brain atrophy                           |
| Mitaki et al.113               | 2017 | 4,024      | 62            | 1.5                    | 4.1            | WMH (lobar CMB), low TC and HDL-C (deep CMB)    |
| Shunyi Study114                | 2018 | 1,211      | 56            | 3.0                    | 10.6           | Age, hypertension (deep CMB), male gender, low LDL-C (deep CMB) |

Note that all studies used gradient-echo T2* weighted sequences.

CMB, cerebral microbleed; MRI, magnetic resonance imaging; T, Tesla; HTN, hypertension; SSI, small subcortical infarct; WMH, white matter hyperintensities; APOE ε4, apolipoprotein ε4; SBP, systolic blood pressure; NR, not reported; TC, total cholesterol; HDL-C, high-density lipoprotein-C; LDL-C, low-density lipoprotein-C.

GRE in the RS, CMB prevalence was 18% in individuals aged 60 to 69 years and 38% in patients older than 80.116 In addition, three studies68,110,115 have found higher rates of CMB in males, although other studies have not reported any gender differences in CMB prevalence.107 As seen in other CSVD biomarkers, smoking was also identified as a risk factor in two studies106,107 while diabetes and hypercholesterolemia may be less important (Table 2).68,113 Given the overlap of risk factors in CMB, WMH, and lacunes, there are likely shared underlying mechanisms that give rise to these biomarkers. Indeed, several studies have demonstrated an increased prevalence of CMB if concomitant WMH and lacunes were present.106,107,111,113

As with other biomarkers, the location of CMB may be reflective of distinct underlying etiologies. In the ASPS, all individuals with deep CMB had hypertension, whereas only 50% of individuals with cortico-subcortical CMB had hypertension.107 In the Framingham Study,108,109 almost three-fourths of the study population had CMB in the cortex, whereas 23% were located in deep regions. Unlike the aforementioned studies, hypertension was not associated with CMB, perhaps explained by the fact that this study included fewer subjects with deep CMB (of which hypertension is more related). In the Age Gene/Environment Susceptibility (AGES)-Reykjavik study,117 larger microbleeds were associated with hypertension, and unlike the ASPS, CMB presence was associated with ApoE ε4 homozygosity.110 Similar to the Framingham Study, 70% of subjects had CMB located in cortex, whereas 11% had deep CMBs, and 19% had infratentorial CMB. Based on these findings, CAA seemed prevalent in their population, and given the association with ApoE, CAA was likely the etiologic culprit. From the RS,116 ApoE ε4 carriers had more lobar CMB compared to noncarriers, whereas patients with cardiovascular risk factors (hypertension, smoking), silent lacunar infarcts, and WMH had more deep or infratentorial CMB. These findings correlate with observed findings in ICH,118 and arterial stiffness findings in stroke patients.119 Interestingly, in a follow-up analysis of the RS,120 it was shown that CMB were more prevalent (odds ratio [OR], 1.71) in patients taking antithrombotic medications (platelet aggregation inhibitors), but not in patients on anticoagulant medications. However, it is worth noting that CMB prevalence may be confounded by some indications for antiplatelet treatment, such as stroke.121 Patients with strictly lobar CMB were found in a higher proportion among aspirin users (OR, 2.70) compared to carbasalate calcium users (a combination formula of calcium acetylsalicylate and urea; OR, 1.16), suggesting that aspirin worsens CMB burden in patients with CAA.

As with other biomarkers, location of CMB may be reflective of distinct underlying etiologies. In the ASPS, all individuals with deep CMB had hypertension, whereas only 50% of individuals with cortico-subcortical CMB had hypertension.107 In the Framingham Study,108,109 almost three-fourths of the study population had CMB in the cortex, whereas 23% were located in deep regions. Unlike the aforementioned studies, hypertension was not associated with CMB, perhaps explained by the fact that this study included fewer subjects with deep CMB (of which hypertension is more related). In the Age Gene/Environment Susceptibility (AGES)-Reykjavik study,117 larger microbleeds were associated with hypertension, and unlike the ASPS, CMB presence was associated with ApoE ε4 homozygosity.110 Similar to the Framingham Study, 70% of subjects had CMB located in cortex, whereas 11% had deep CMBs, and 19% had infratentorial CMB. Based on these findings, CAA seemed prevalent in their population, and given the association with ApoE, CAA was likely the etiologic culprit. From the RS,116 ApoE ε4 carriers had more lobar CMB compared to noncarriers, whereas patients with cardiovascular risk factors (hypertension, smoking), silent lacunar infarcts, and WMH had more deep or infratentorial CMB. These findings correlate with observed findings in ICH,118 and arterial stiffness findings in stroke patients.119 Interestingly, in a follow-up analysis of the RS,120 it was shown that CMB were more prevalent (odds ratio [OR], 1.71) in patients taking antithrombotic medications (platelet aggregation inhibitors), but not in patients on anticoagulant medications. However, it is worth noting that CMB prevalence may be confounded by some indications for antiplatelet treatment, such as stroke.121 Patients with strictly lobar CMB were found in a higher proportion among aspirin users (OR, 2.70) compared to carbasalate calcium users (a combination formula of calcium acetylsalicylate and urea; OR, 1.16), suggesting that aspirin worsens CMB burden in patients with CAA.

As with other biomarkers, location of CMB may be reflective of distinct underlying etiologies. In the ASPS, all individuals with deep CMB had hypertension, whereas only 50% of individuals with cortico-subcortical CMB had hypertension.107 In the Framingham Study,108,109 almost three-fourths of the study population had CMB in the cortex, whereas 23% were located in deep regions. Unlike the aforementioned studies, hypertension was not associated with CMB, perhaps explained by the fact that this study included fewer subjects with deep CMB (of which hypertension is more related). In the Age Gene/Environment Susceptibility (AGES)-Reykjavik study,117 larger microbleeds were associated with hypertension, and unlike the ASPS, CMB presence was associated with ApoE ε4 homozygosity.110 Similar to the Framingham Study, 70% of subjects had CMB located in cortex, whereas 11% had deep CMBs, and 19% had infratentorial CMB. Based on these findings, CAA seemed prevalent in their population, and given the association with ApoE, CAA was likely the etiologic culprit. From the RS,116 ApoE ε4 carriers had more lobar CMB compared to noncarriers, whereas patients with cardiovascular risk factors (hypertension, smoking), silent lacunar infarcts, and WMH had more deep or infratentorial CMB. These findings correlate with observed findings in ICH,118 and arterial stiffness findings in stroke patients.119 Interestingly, in a follow-up analysis of the RS,120 it was shown that CMB were more prevalent (odds ratio [OR], 1.71) in patients taking antithrombotic medications (platelet aggregation inhibitors), but not in patients on anticoagulant medications. However, it is worth noting that CMB prevalence may be confounded by some indications for antiplatelet treatment, such as stroke.121 Patients with strictly lobar CMB were found in a higher proportion among aspirin users (OR, 2.70) compared to carbasalate calcium users (a combination formula of calcium acetylsalicylate and urea; OR, 1.16), suggesting that aspirin worsens CMB burden in patients with CAA.

Even in clinically healthy persons, the presence of CMB correlates with numerous future risks. In the RS, the presence of CMB almost doubled the risk of ischemic stroke in a 5-year period, with greater CMB count associated with higher stroke risk.118 In the PROSPER trial, subjects with greater than 1 CMB had a six-fold increase in stroke-related death than those without CMB.122 Nonlobar CMB were associated with an increased risk of cardiovascular death whereas lobar CMB was associated with an elevated risk of stroke-related death.123 CMB have also been associated with gait disturbances in nondemented persons.112,124 Furthermore, subjects with ≥2 CMB performed poorly on tests of processing speed and executive function, especially those with multiple, deep or infratentorial CMB.125 The presence of these deep CMB doubled the risk of
vascular dementia (VaD). Subjects with both CMB and con-
comitant retinopathy were most likely to exhibit slow process-
ing speeds, poor executive function, and VaD. Other studies
have shown that subjects with numerous (≥5) lobar CMB had
more robust associations with cognitive dysfunction than did
subjects with deep CMB. However, in the Framingham
Heart Study, strictly lobar CMB were not associated with an
increased risk of dementia. Collectively, these studies suggest
that deep CMB may contribute to cognitive decline through
mechanisms distinct from lobar CMB-associated cognitive dys-
function. The former like reflects sporadic, non-amyloid
CSVD whereas the latter reflects CAA.

Enlarged perivascular spaces

PVSs, sometimes referred to as Virchow–Robins spaces, are lin-
ear (but can be ovoid or round) projections that follow the path
of blood vessels. Their significance is unclear, although they may
be involved in the drainage of interstitial fluid and may be im-
plicated in neurological diseases. Normally, they are not well
visualized by conventional MRI; however, as these spaces dilate
(with age or other pathological conditions), they may be seen as
fluid-filled spaces in both the gray and white matter. They are
usually <3 mm in maximal diameter, a cutoff that has often
been used to distinguish these from lacunes, which also contain
a hyperintense T2 rim surrounding the cavitation.

Similar to other biomarkers, the spatial distribution of PVS
may reflect distinct mechanisms such that deep PVS are likely
caued by hypertensive-CSVD whereas white matter PVS may be
more driven by CAA. Such anatomical distinctions have also
been observed in PVS found after ICH. In patients presenting
to a memory clinic, white matter PVS were associated with lobar
CMB whereas basal ganglia PVS were associated with older age,
hypertension, and higher WMH volumes. Similarly, in a healthy
Japanese cohort, basal ganglia PVS were associated with in-
fratentorial CMB, and centrum semiovale PVS were associated
with strictly lobar CMB. Furthermore, basal ganglia PVS were
associated with hypertension, lacunes, and severe WMH sug-
uggesting that these CSVD markers share common substrates.
In the Three-City (3C)-Dijon Magnetic Resonance Imaging Study, in
addition to the basal ganglia and white matter, PVS were also
observed in the hippocampus and hypothalamus. In this study,
PVS were found in all subjects, with approximately one-third be-
ing large (>3 mm). Men appeared to have more basal ganglia
PVS than woman, although this has not been replicated in other
studies. The severity of both basal ganglia and white matter
PVS correlated with increasing age. With increasing WMH
volumes and lacunes, the odds of having more severe PVS in the
basal ganglia was higher than in white matter.

While several of these studies employ 3 mm as a size cutoff
to distinguish PVS from lacunes, in imaging-pathological cor-
relation studies, an absolute cutoff size has not been estab-
lished. PVS above this size cutoff (termed large PVS) may ac-
ually be common and were found in approximately one-sixth
of the subjects in the AGES-Reykjavik Study. The majority of
these large PVS were located in the basal ganglia and only a
small fraction of subjects had exclusively white matter PVS.
After controlling for age and sex, the presence of these deep
large PVS was associated with silent subcortical infarcts and
WMH progression. CMB were associated with both deep and
white matter large PVS. The concurrent presence of PVS and
other markers of CVD suggests that there are common under-
lying mechanisms at play.

Although their significance in either healthy or diseased
populations is not well understood, the presence of PVS may
confer an increased risk of cognitive decline. In one small study,
higher numbers of basal ganglia and centrum semiovale PVS
were associated with poor performance on neuropsychological
testing. Independent of other cerebrovascular risk factors,
large PVS (>3 mm) were associated with poor processing
speeds as well as a four-fold increase in VaD risk, but not Al-
zheimer's dementia (AD) or all-cause dementia risk. This is
consistent with previous studies that observed PVS in higher
frequencies in patients with VaD compared to AD. Furthermore,
in another population-based study of elderly nondemented
subjects, patients with the highest degree of both white matter
and basal ganglia PVS were most likely to develop dementia over a 4-year period.

Cortical superficial siderosis

cSS are chronic hemorrhagic products that lie under the pia
matter or in the subarachnoid space and are due to a variety of
causes including small vascular malformations or CAA. They
are best visualized on paramagnetic MRI sequences given their
hemosiderin composition, and appear as a linear hypointensity
over the cortex.

In the RS, cSS were found in 0.7% of individuals, all of which
had lobar CMB. In these individuals, cSS was located near re-
gions of lobar CMB (frontal and occipital areas). In the most re-
cent Rotterdam data, the prevalence of cSS was 0.4% (n=3,401). These 15 individuals had concurrent CMB, the ma-

US: https://doi.org/10.5853/jos.2018.03608
sion of cSS on a follow-up scan. These individuals had several lobar CMB on baseline scans ranging from 7 to 130 CMB.

In another population-based study (n=1,412)\textsuperscript{143} of individuals aged 50 to 89 (of which a portion had dementia or mild cognitive impairment\textsuperscript{144}), using data from the Mayo Clinic Study of Aging, 13 subjects (0.9%) were found to have cSS. Unlike the RS, only about one-fifth of these patients had concurrent CMB, a finding which is consistent with other reports.\textsuperscript{145} While the presence of the ApoE ε4 allele did not influence cSS burden, subjects with cSS were more likely to have the presence of the APOE ε2 allele, which is associated with CAA.\textsuperscript{146} In a subset of patients who underwent Pittsburgh compound B (PiB) positron emission tomographic scans, those with cSS were more likely to be PiB positive (suggestive of high β-amyloid burden). Two patients with disseminated cSS had follow-up scans which demonstrated progression of both cSS and CMB. Although small numbers of subjects had both PiB and APOE data, these results suggest that cSS is intimately associated with CAA. Collectively, these findings suggest that cSS may be a marker of CAA-related CSVD rather than hypertensive arteriopathy. cSS is likely a rare finding in healthy populations but is probably exclusively related to coincident CAA pathology when it is found.

**Cerebral microinfarcts**

CMI are microscopic, presumed ischemic infarcts, mostly identified on pathological analysis, but can be seen on 7T MRI, and occasionally on 3T studies.\textsuperscript{147-150} Given their ability to escape detection using standard neuroimaging protocols (1.5T MRI), CMI have not been evaluated extensively in healthy individuals. Because their small size (average of 0.2 to 1 mm in diameter) is below the spatial resolution (1 mm\textsuperscript{2}) for most conventional MRI field strengths, higher strength MRI machines are needed to visualize them.\textsuperscript{147,151-153} While most of the available data on CMI has come through post-mortem analysis by 7T MRI, recently, several groups have reported the ability to detect these lesions on 3T MRI \textit{in vivo}.\textsuperscript{149,150,154-156} However, the sensitivity of detection of 3T is limited compared to 7T,\textsuperscript{150} and can only detect “large” CMI (1 to 3 mm; whereas 7T can detect CMI <1 mm).\textsuperscript{152} As \textit{in vivo} detection of CMI is relatively recent, it has not been incorporated into STRIVE definitions, and there have been no consensus definitions established. In some studies,\textsuperscript{148,150} CMI have been defined on 3T MRI as hypointense on T1-weighted images, hyperintense or isointense on FLAIR and T2-weighted images, distinct from PVS, <5 mm in maximum diameter, and perpendicular to the cortical surface.

In patients presenting to a memory clinic in Singapore, the prevalence of CMI determined by 3T MRI was 32%.\textsuperscript{149} The presence of CMI was associated with hyperlipidemia, history of stroke, and cardiovascular disease (even after controlling for macroinfarcts). Furthermore, the presence of cortical CMI was associated with executive dysfunction as well as lower scores on neurocognitive testing with relative sparing of areas involved in subcortical disease (attention and visuomotor speed). Not surprisingly, patients with cortical CMI were more likely to be diagnosed with VaD than those without CMI, although previous reports have indicated that the prevalence of individuals with CMI was relatively the same between AD patients and non-demented controls.\textsuperscript{152,155} CMI were associated with both deep and lobar CMB, increased WMH burden, and small brain volumes. Even after adjusting for WMH, CMB, or macroinfarcts, CMI were independently associated with VCI.\textsuperscript{149} Furthermore, CMI were associated with cortical and subcortical macroinfarcts (and were not always restricted to the hemisphere of the infarct). CMI were also associated with intracranial stenosis of the vessel supplying the affected territory. These findings have been reproduced in stroke patients, in which it was determined that internal carotid artery stenosis was an independent risk factor for the development of CMI, and CMI development was associated with higher stroke recurrence rates.\textsuperscript{150} Overall, this study of memory clinic patients suggests that CMI are a common finding in elderly patients with cognitive dysfunction and is in accordance with other population-based neuropathological studies.\textsuperscript{159} This study also reported hyperlipidemia as a risk factor for CMI whereas previous population-based autopsy studies identified hypertension as the causative agent.\textsuperscript{160,161} Interestingly, in another analysis using this Singapore cohort,\textsuperscript{162} 29% of subjects exhibited CMI on 3T MRI. These patients had an increased frequency of hypertension, hyperlipidemia, cardiac disease, and were found to have higher levels of subclinical cardiac biomarkers including N-terminal pro-brain natriuretic peptide (nT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) (after adjusting for age, sex, cardiac disease, and other cerebrovascular risk factors). In addition, there was an association between atrial fibrillation, ischemic heart disease, and congestive heart failure with cortical CMI. Indeed, in one neuropathological study, it was suggested that CMI may be caused by microemboli.\textsuperscript{163} The constellations of these associations including hyperlipidemia, intracranial atherosclerosis, and cardiac disease suggests that CMI have a heterogeneous etiology that arises from shared pathways of CSVD, cardioembolism, and large vessel stenosis.

In another large, population-based study that recruited participants from the multiethnic Epidemiology of Dementia in Singapore Study (EDIS; n=1,598), 6.3% exhibited at least one CMI.\textsuperscript{164,165} The majority of these were located in the parietal
 lobes (42%), and to a lesser extent, frontal (21%), occipital (12%), and temporal lobes consistent with one earlier small study using 7T MRI. The presence of other markers of CSVD (including lacunar infarcts, WMH, and CMB) as well as macroinfarcts and intracranial stenosis was greater in patients with CMI. Risk factors associated with CMI were increasing age, Malay ethnicity, hypertension, diabetes, and history of stroke. Although not consistent with previous reports,166,167 the association of CMI with diabetes suggests that CMI may also be caused by microatheromatous disease at penetrating capillaries. While it was not significant in this study, cigarette smoking has been associated with the presence of CMI in other studies.168 In addition to cerebrovascular risk factors, subjects with CMI were more likely to have moderate cognitive impairment and dementia.169 Furthermore, the presence of CMI was associated with poor performance on neuropsychological testing even after controlling for lacunar infarcts. Collectively, CMI are independently associated with neurocognitive impairment as has been observed in neuropsychological studies.169

Very few studies have examined whether the anatomical location of CMI suggests different risk factors or underlying pathologies. In one recent large population-based neuropathological study of elderly community dwelling individuals (n=1,066),170-172 CMI were found in one-third of subjects. The odds of having one or more CMI were increased in patients with atherosclerosis, arteriolosclerosis, and CAA. However, in a subgroup analysis, only atherosclerosis and arteriolosclerosis were associated with subcortical CMI, whereas CAA was associated with cortical CMI. Similar to other biomarkers, cortical CMI may be associated with CAA pathology whereas subcortical CMI may be due to other mechanisms such as hypertension.

### Screening for CSVD

The major clinical features and associated risk factors for CSVD biomarkers are summarized below (Table 3). Currently, screening of asymptomatic individuals for CSVD is not recommended.173 The major reasons MRIs are not performed in healthy populations is cost and lack of intervenable measures if asymptomatic CSVD is identified. However, more cost-effective methods of screening for CSVD may be able to select at-risk patients, especially those in high-risk populations, such as women or African Americans. These initial studies, if abnormal, can prompt further testing including MRI.

In patients that have received a brain MRI, a total SVD score can be calculated to assess the total burden of CSVD.174 This visually rated score (ranging from 0 to 4) incorporates WMH, lacunes, CMB, and PVS, and reflects the amount of brain injury attributable to CSVD.175 Not surprisingly, hypertension, age, male gender, and smoking are associated with higher SVD scores, highlighting the concept of shared underlying pathogenic mechanisms. Although it has not been widely adopted in clinical practice, this score can assist in stratifying patients at risk for ischemic stroke176 or cognitive impairment. Furthermore, it can serve as a surrogate combined marker for CSVD in clinical trials focused on secondary prevention.174

In cross-sectional population-based studies, numerous biomarkers such as fibrinogen, C-reactive protein (CRP), interleukin-6, neurofilament light chain, homocysteine, and D-dimer have been associated with the presence of CSVD markers such as WMH, lacunes, and PVS.177-179 In two longitudinal population-based studies, only intercellular adhesion molecule 1 (ICAM-1) and CRP have been found to be associated with WMH progression.

### Table 3. Summary of biomarkers

| Neuroimaging markers | Pathological correlate | MRI appearance | Risk factors | Associated CSVD subtype | Sequelae |
|----------------------|------------------------|----------------|--------------|--------------------------|----------|
| WMH                  | Chronically hypoperfused brain parenchyma | Hyperintense on T2 and FLAIR, hypointense on T1 (variable size) | Age, smoking, hypertension | HTN-CSVD, CAA | IS, ICH, VaD |
| Lacunes              | Chronic fluid-filled end-product of small subcortical infarcts | Central hypointensity with surrounding rim of hyperintensity on FLAIR (3 to 15 mm) | Age, smoking, hypertension | HTN-CSVD, CAA | IS, ICH, VaD |
| CMB                  | Foci of hemosiderin-laden macrophages | Round/oval shaped signal void (≤10 mm) with blooming artifact on T2*, GRE, SWI | Age, smoking, hypertension | HTN-CSVD, CAA | IS, ICH, VaD |
| PVS                  | Interstitial fluid-filled spaces surrounding blood vessels | Linear cavitation without hyperintense T2 rim on FLAIR (<3 mm) | Hypertension | HTN-CSVD, CAA | VaD |
| cSS                  | Chronic hemorrhagic products underlying pia mater | Curvilinear hypointensity that follows gyral surface on T2*, GRE, SWI | Unknown | CAA | ICH |
| CMI                  | Microscopic ischemic infarcts | Hypointense on T1, hypointense on T2/FLAIR (<5 mm) | Heterogenous | HTN-CSVD, CAA | VaD |

MRI, magnetic resonance imaging; CSVD, cerebral small vessel disease; WMH, white matter hyperintensity; FLAIR, fluid attenuated inversion recovery; HTN, hypertensive; CAA, cerebral amyloid angiopathy; IS, ischemic stroke; ICH, intracerebral hemorrhage; VaD, vascular dementia; CMB, cerebral microbleed; GRE, gradient echo; SWI, susceptibility-weighted imaging; PVS, perivascular spaces; cSS, cortical superficial siderosis; CMI, cerebral microinfarcts.
...have been conflicting results in these studies, the use of biomarkers for routine screening of CSVD is not recommended in healthy populations. These markers may be incidental, and their significance and progression remain unclear. Several of these biomarkers, such as homocysteine, are not entirely specific for CSVD and can be elevated in other stroke subtypes. Moreover, interpretation of cut-off values and heterogeneity among studies confounds interpretation of results. Future efforts should be aimed at identifying specific markers for asymptomatic CSVD, markers that represent accelerated CSVD progression, and markers that predict conversion from asymptomatic to symptomatic CSVD.

Treatment and future directions

It remains unclear how to best identify patients with asymptomatic CSVD. Furthermore, it is unclear whether treatment of CSVD at an asymptomatic disease stage is necessary or beneficial. Perhaps the most available data comes from studies on WMH in community-dwelling individuals. As hypertension seems to play the biggest role in CSVD pathogenesis, it is not surprising that the majority of these studies focus on hypertension reduction. Early trials have demonstrated higher WMH volumes in patients with uncontrolled hypertension compared to those receiving antihypertensive medications. Furthermore, several trials have demonstrated reduced WMH progression with BP reduction therapy, although these results were not replicated in all studies. When these trials were analyzed in a recent meta-analysis, less WMH progression was observed in subjects taking antihypertensive medications. The optimal timing for usage of these antihypertensives remains unclear, but presumably, earlier intervention may be more beneficial. Whether antihypertensive medications have similar effects on other CSVD biomarkers in unknown.

In addition to antihypertensives, other studies have examined statin usage, although very few population-based studies demonstrate an association of hyperlipidemia with CSVD. Three studies have demonstrated reductions in WMH with lipid-lowering drugs, while other studies did not show any benefit. Although the association between diabetes and CSVD is controversial, hyperglycemia was shown to influence WMH progression in one study. No studies, however, have evaluated glycemic control on WMH reduction. Lastly, in one meta-analysis, half of the studies demonstrated WMH reduction with exercise, but the other half did not.

Although antiplatelet agents have been extensively evaluated in the primary and secondary prevention of patients with lacunar stroke, there have been few studies examining the cerebrovascular effects of antiplatelet agents in healthy populations. In one small study, healthy subjects who underwent MRI screening for WMH were given antiplatelet therapy. In a follow-up MRI study 5 years later, there was no difference in deep or periventricular WMH progression among patients taking antiplatelet agents. Given the small observational nature of this study, larger studies will need to be performed to fully elucidate the effects of antiplatelet therapy on CSVD prevention. However, it should be noted that these therapies may be counterbalanced by an increased risk of CMB (and subsequent ICH).

Some patients with CSVD may exhibit minimal or no clinical symptoms while other patients develop stroke, cognitive impairment, and other long-term morbidity. Early detection of clinically significant CSVD is particularly difficult for reasons including (1) utility of screening in the general population and (2) lack of full understanding of the significance of CSVD biomarkers. Part of the challenge in developing a validated brain biomarker for CSVD is the complex pathways that underlie the disease. Risk prediction models to select populations at higher risk are urgently needed.

Disclosure

The authors have no financial conflicts of interest.

Acknowledgments

This work was supported by the National Institutes of Health (R01AG047975, R01AG026484, P50AG005134, and K23AG02872605 to AV and R25NS065743 to RWR).

References

1. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med 2015;372:11-20.
2. Campbell BC, Mitchell PJ, Kleinitj TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med 2015;372:1009-1018.
3. Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med 2015;372:2296-2306.
4. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N Engl J Med 2015;372:2285-2295.
5. Brackad S, Ducrocq X, Mas JL, Soudant M, Oppenheim C, Moulin T, et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a ran...
domised controlled trial. *Lancet Neurol* 2016;15:1138-1147.
6. Charidimou A, Pantoni L, Love S. The concept of sporadic cerebrovascular small vessel disease: a road map on key definitions and current concepts. *Int J Stroke* 2016;11:6-18.
7. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. *Lancet Neurol* 2010;9:689-701.
8. Whitman GT, Tang Y, Lin A, Baloh RW. A prospective study of cerebral white matter abnormalities in older people with gait dysfunction. *Neurology* 2001;57:990-994.
9. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. *N Engl J Med* 2003;348:1215-1222.
10. Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. *Lancet Neurol* 2007;6:611-619.
11. Russo E, Leo A, Scichiliano F, Donato A, Ferlazzo E, Gasparini S, et al. Cerebral small vessel disease predisposes to temporal lobe epilepsy in spontaneously hypertensive rats. *Brain Res Bull* 2017;130:245-250.
12. de Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hofman A, Jolles J, et al. Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. *Ann Neurol* 2000;47:145-151.
13. van der Holst HM, van Uden IW, Taludhar AM, de Laat KF, van Norden AG, Norris DG, et al. Cerebral small vessel disease and incident parkinsonism: The RUN DMC study. *Neurology* 2015;85:1569-1577.
14. Wardlaw JM, Smith C, Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. *Lancet Neurol* 2013;12:483-497.
15. Søndergaard CB, Nielsen JE, Hansen CK, Christensen H. Hereditary cerebral small vessel disease and stroke. *Clin Neurol Neurosurg* 2017;155:45-57.
16. Choi JC. Genetics of cerebral small vessel disease. *J Stroke* 2015;17:7–16.
17. Wermer MJH, Greenberg SM. The growing clinical spectrum of cerebral amyloid angiopathy. *Curr Opin Neurol* 2018;31:28-35.
18. Charidimou A, Boulouis G, Gurok ME, Ayata C, Bacskaï BJ, Frosch MP, et al. Emerging concepts in sporadic cerebral amyloid angiopathy. *Brain* 2017;140:1829-1850.
19. Greenberg SM. Small vessels, big problems. *N Engl J Med* 2006;354:1451-1453.
20. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol* 2013;12:822-838.
21. Price TR, Manolio TA, Kronmal RA, Kittner SJ, Yue NC, Robbins J, et al. Silent brain infarction on magnetic resonance imaging and neurological abnormalities in community-dwelling older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. *Stroke* 1997;28:1158-1164.
22. Leary MC, Saver JL. Annual incidence of first silent stroke in the United States: a preliminary estimate. *Cerebrovasc Dis* 2003;16:280-285.
23. Westover MB, Bianchi MT, Yang C, Schneider JA, Greenberg SM. Estimating cerebral microinfarct burden from autopsy samples. *Neurology* 2013;80:1365-1369.
24. Auriel E, Westover MB, Bianchi MT, Reijmer Y, Martinez-Ramirez S, Ni J, et al. Estimating total cerebral microinfarct burden from diffusion-weighted imaging. *Stroke* 2015;46:2129-2135.
25. van Veluw SJ, Shih AY, Smith EE, Chen C, Schneider JA, Wardlaw JM, et al. Detection, risk factors, and functional consequences of cerebral microinfarcts. *Lancet Neurol* 2017;16:730–740.
26. Feng C, Bai X, Xu Y, Hua T, Liu YX. The ‘silence’ of silent brain infarctions may be related to chronic ischemic preconditioning and nonstrategic locations rather than to a small infarct size. *Clinics (Sao Paulo)* 2013;68:365-369.
27. Shi Y, Wardlaw JM. Update on cerebral small vessel disease: a dynamic whole-brain disease. *Stroke Vasc Neurol* 2016;1:83-92.
28. van Leijsen EMC, de Leeuw FE, Tuladhar AM. Disease progression and regression in sporadic small vessel disease—insights from neuroimaging. *Clin Sci (Lond)* 2017;131:1191-1206.
29. Hachinski VC, Potter P, Mesker H. Leuko-araiosis. *Arch Neurol* 1987;44:21-23.
30. Pantoni L, Garcia JH. The significance of cerebral white matter abnormalities 100 years after Binswanger’s report: a review. *Stroke* 1995;26:1293-1301.
31. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. *Stroke* 1997;28:652-659.
32. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ* 2010;341:c3666.
33. Topkian R, Barrick TR, Howe FA, Markus HS. Blood-brain barrier permeability is increased in normal-appearing white matter in patients with lacunar stroke and leukoaraiosis. *J Neuro Neurosurg Psychiatry* 2010;81:192-197.
34. Wardlaw JM, Valdés Hernández MC, Muñoz-Maniega S. What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. *J Am Heart Assoc* 2015;4:001140.
35. Longstreth WT Jr, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people.
The Cardiovascular Health Study. Stroke 1996;27:1274-1282.

36. Longstreth WT Jr, Arnold AM, Beauchamp NJ Jr, Manolio TA, Lefkowitz D, Jungreis C, et al. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 2005;36:56-61.

37. de Leeuw FE, de Groot JC, Achten E, Oudkerk M, Ramos LM, Heijboer R, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neural Neurosurg Psychiatry 2001;70:9-14.

38. van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MM. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study. Stroke 2008;39:2712-2719.

39. Liao D, Cooper L, Cai J, Toole JF, Bryan NR, Hutchinson RG, et al. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control. The ARIC Study. Atherosclerosis Risk in Communities Study. Stroke 2008;39:2712-2719.

40. Schmidt R, Fazekas F, Kapeller P, Schmidt H, Hartung HP. MRI white matter hyperintensities: three-year follow-up of the Austrian Stroke Prevention Study. Neurology 1999;53:132-139.

41. Schmidt R, Ropele S, Enzinger C, Petrovic K, Smith S, Schmidt H, et al. White matter lesion progression, brain atrophy, and cognitive decline: the Austrian Stroke Prevention Study. Ann Neurol 2005;58:610-616.

42. Power MC, Deal JA, Sharrett AR, Jack CR Jr, Knopman D, Mosley TH, et al. Smoking and white matter hyperintensity progression: the ARIC-MRI Study. Neurology 2015;84:841-848.

43. Jeerakathil T, Wolf PA, Beiser A, Massaro J, Seshadri S, D’Agostino RB, et al. Stroke risk profile predicts white matter hyperintensity volume: the Framingham Study. Stroke 2004;35:1857-1861.

44. Debette S, Seshadri S, Beiser A, Au R, Himail JJ, Palumbo C, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology 2011;77:461-468.

45. Schmidt R, Petrovic K, Ropele S, Enzinger C, Fazekas F. Progression of leukoaraiosis and cognition. Stroke 2007;38:2619-2625.

46. Bokura H, Kobayashi S, Yamaguchi S, Iijima K, Nagai A, Toyoda G, et al. Silent brain infarction and subcortical white matter lesions increase the risk of stroke and mortality: a prospective cohort study. J Stroke Cerebrovasc Dis 2006;15:57-63.

47. Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991;1:263-276.

48. Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol 1993;3:358-366.

49. Price TR, Psaty B, O’Leary D, Burke G, Gardin J. Assessment of cerebrovascular disease in the Cardiovascular Health Study. Ann Epidemiol 1993;3:504-507.

50. Manolio TA, Kronmal RA, Burke GL, Poirier V, O’Leary DH, Gardin JM, et al. Magnetic resonance abnormalities and cardiovascular disease in older adults. The Cardiovascular Health Study. Stroke 1994;25:318-327.

51. Longstreth WT Jr, Bernick C, Manolio TA, Bryan N, Jungreis CA, Price TR. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. Arch Neurol 1998;55:1217-1225.

52. Bernick C, Kuller L, Dulberg C, Longstreth WT Jr, Manolio T, Beauchamp N, et al. Silent MRI infarcts and the risk of future stroke: the Cardiovascular Health Study. Neurology 2001;57:1222-1229.

53. Longstreth WT Jr, Dulberg C, Manolio TA, Lewis MR, Beauchamp NJ Jr, O’Leary D, et al. Incidence, manifestations, and predictors of brain infarcts defined by serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 2002;33:2376-2382.

54. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991;7:403-422.

55. van Dijk EJ, Prins ND, Veerme SE, Koudstaal PJ, Breteler MM. Frequency of white matter lesions and silent lacunar infarcts. J Neurol Transm Suppl 2002;62:25-39.

56. Veerme SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2002;33:21-25.

57. Vemooij MW, Ikram MA, Tanghe HL, Vincent AJ, Hofman A, Krestin GP, et al. Incidental findings on brain MRI in the general population. N Engl J Med 2007;357:1821-1828.

58. Poels MM, Zaccai K, Verwoert GC, Vemooij MW, Hofman A, van der Lugt A, et al. Arterial stiffness and cerebral small vessel disease: the Rotterdam Scan Study. Stroke 2012;43:2637-2642.

59. Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley BM, et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER), PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol 1999;84:1192-1197.

60. van den Heuvel DM, Admiraal-Behlou F, ten Dam VH, Olof-
sen H, Bollen EL, Murray HM, et al. Different progression rates for deep white matter hyperintensities in elderly men and women. *Neurology* 2004;63:1699–1701.

61. The ARIC investigators. The Atherosclerosis Risk in Communities (ARIC) study: design and objectives. *Am J Epidemiol* 1989;129:687–702.

62. Mosley TH Jr, Knopman DS, Catellier DJ, Bryan N, Hutchinson RG, Grothues CA, et al. Cerebral MRI findings and cognitive functioning: the Atherosclerosis Risk in Communities study. *Neurology* 2005;64:2056–2062.

63. Liao D, Cooper L, Cai J, Toole J, Bryan N, Burke G, et al. The prevalence and severity of white matter lesions, their relationship with age, ethnicity, gender, and cardiovascular disease risk factors: the ARIC Study. *Neuroepidemiology* 1997;16:149–162.

64. Gottesman RF, Coresh J, Catellier DJ, Sharrett AR, Rose KM, Coker LH, et al. Blood pressure and white-matter disease progression in a biethnic cohort: Atherosclerosis Risk in Communities (ARIC) study. *Stroke* 2010;41:3–8.

65. Wolma J, Nederkoorn PJ, Goossens A, Vergouwen MD, van Schaik IN, Vermeulen M. Ethnicity a risk factor? The relation between ethnicity and large- and small-vessel disease in White people, Black people, and Asians within a hospital-based population. *Eur J Neurol* 2009;16:522–527.

66. Hilal S, Mok V, Youn YC, Wong A, Ikram MK, Chen CL. Prevalence, risk factors and consequences of childhood small vessel cerebral vessel diseases: data from three Asian countries. *J Neurol Neurosurg Psychiatry* 2017;88:669–674.

67. Sudre CH, Smith L, Atkinson D, Chaturvedi N, Ourisel S, Barkhof F, et al. Cardiovascular risk factors and white matter hyperintensities: difference in susceptibility in south Asians compared with Europeans. *J Am Heart Assoc* 2018;7:e00533.

68. Han F, Zhai FF, Wang Q, Zhou LX, Ni J, Yao M, et al. Prevalence and risk factors of cerebral small vessel disease in a Chinese population-based sample. *J Stroke* 2018;20:239–246.

69. van Zagten M, Boiten J, Kessels F, Lodder J. Significant progression of white matter lesions and small deep (lacunar) infarcts in patients with stroke. *Arch Neurol* 1996;53:650–655.

70. Sachdev P, Wen W, Chen X, Brodaty H. Progression of white matter hyperintensities in elderly individuals over 3 years. *Neurology* 2007;68:214–222.

71. Wahlund LO, Almkvist O, Basun H, Julin P. MRI in successful aging, a 5-year follow-up study from the eighth to ninth decade of life. *Magn Reson Imaging* 1996;14:601–608.

72. Gouw AA, van der Flier WM, Fazekas F, van Straaten EC, Pantoni L, Poggesi A, et al. Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. *Stroke* 2008;39:1414–1420.

73. Taylor WD, MacFall JR, Provenzale JM, Payne ME, McQuoid DR, Steffens DC, et al. Serial MR imaging of volumes of hyperintense white matter lesions in elderly patients: correlation with vascular risk factors. *AJR Am J Roentgenol* 2003;181:571–576.

74. Kuller LH, Longstreth WT Jr, Arnold AM, Bernick C, Bryan RN, Beauchamp NJ Jr, et al. White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke. *Stroke* 2004;35:1821–1825.

75. Schmidt R, Fazekas F, Enzinger C, Ropele S, Kapeller P, Schmidt H. Risk factors and progression of small vessel disease-related cerebral abnormalities. *J Neuro Transm Suppl* 2002;62:47–52.

76. Schmidt R, Enzinger C, Ropele S, Schmidt H, Fazekas F; Austrian Stroke Prevention Study. Progression of cerebral white matter lesions: 6-year results of the Austrian Stroke Prevention Study. *Lancet* 2003;361:2046–2048.

77. Verhaaren BF, Vernooij MW, de Boer R, Hofman A, Niessen WJ, van der Lugt A, et al. High blood pressure and cerebral white matter lesion progression in the general population. *Hypertension* 2013;61:1354–1359.

78. Debette S, Beiser A, DeCarli C, Au R, Himali JJ, Kelly-Hayes M, et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. *Stroke* 2010;41:600–606.

79. Ikram MA, Vernooij MW, Vrooman HA, Hofman A, Breteler MM. Brain tissue volumes and small vessel disease in relation to the risk of mortality. *Neurobiol Aging* 2009;30:450–456.

80. Kerber KA, Whitman GT, Brown DL, Baloh RW. Increased risk of death in community-dwelling older people with white matter hyperintensities on MRI. *J Neurol Sci* 2006;250:33–38.

81. Buyck JF, Dufouil C, Mazoyer B, Maillard P, Ducimetière P, Alpérovitch A, et al. Cerebral white matter lesions are associated with the risk of stroke but not with other vascular events: the 3-City Dijon Study. *Stroke* 2009;40:2327–2331.

82. Tully PJ, Debette S, Mazoyer B, Tzourio C. White matter lesions are associated with specific depressive symptom trajectories among incident depression and dementia populations: three-city Dijon MRI study. *Am J Geriatr Psychiatry* 2017;25:1311–1321.

83. Smith EE, Egorova S, Blacker D, Killiany RJ, Muzikansky A, Dickerson BC, et al. Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. *Arch Neurol* 2008;65:94–100.

84. Silbert LC, Howieson DB, Dodge H, Kaye JA. Cognitive impair-
ment risk: white matter hyperintensity progression matters. *Neurology* 2009;73:120-125.

85. van den Heuvel DM, ten Dam VH, de Craen AJ, Admiraal-Behloul F, Olofson H, Bollen EL, et al. Increase in periventricular white matter hyperintensities parallles decline in mental processing speed in a non-demented elderly population. *J Neurosurg Psychiatry* 2006;77:149-153.

86. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science 1993;261:921-923.

87. Heise V, Fillipini N, Ebmeier KP, Mackay CE. The APOE ε4 allele modulates brain white matter integrity in healthy adults. *Mol Psychiatry* 2011;16:908-916.

88. Sudre CH, Cardoso MJ, Frost C, Barnes J, Barkhof F, Fox N, et al. APOE ε4 status is associated with white matter hyperintensities volume accumulation rate independent of AD diagnosis. *Neurobiol Aging* 2017;53:67-75.

89. Cox SR, Ritchie SJ, Dickie DA, Pattie A, Royle NA, Corley J, et al. Interaction of APOE ε4 and poor glycemic control predicts white matter hyperintensity growth from 73 to 76. *Neurobiol Aging* 2017;54:54-58.

90. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Koudstaal PJ, Oudkerk M, et al. Cerebral white matter lesions and the risk of dementia. *Arch Neurol* 2004;61:1531-1534.

91. Fisher CM. Lacunar strokes and infarcts: a review. *Neurology* 1982;32:871-876.

92. Fisher CM. Lacunes: small, deep cerebral infarcts. *Neurology* 1965;15:774-784.

93. Kimberly WT, Gilson A, Rost NS, Rosand J, Viswanathan A, Smith EE, et al. Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy. *Neurology* 2009;72:1230-1235.

94. Prabhakaran S, Gupta R, Ouyang B, John S, Temes RE, Mohammad Y, et al. Acute brain infarcts after spontaneous intracerebral hemorrhage: a diffusion-weighted imaging study. *Stroke* 2010;41:89-94.

95. Wardlaw JM, Chappell FM, Valdés Hernández MDC, Makin SDJ, Staals J, Shuler K, et al. White matter hyperintensity reduction and outcomes after minor stroke. *Neurology* 2017;89:1003-1010.

96. Moreau F, Patel S, Lauzon ML, McCreary CR, Goyal M, Frayne R, et al. Cavitation after acute symptomatic lacunar stroke depends on time, location, and MRI sequence. *Stroke* 2012;43:1837-1842.

97. Fanning JP, Wong AA, Fraser JF. The epidemiology of silent brain infarction: a systematic review of population-based cohorts. *BMC Med* 2014;12:119.

98. Howard G, Wagenknecht LE, Cai J, Cooper L, Kraut MA, Toole JF. Cigarette smoking and other risk factors for silent cerebral infarction in the general population. *Stroke* 1998;29:913-917.

99. Vermeer SE, Den Heijer T, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM, et al. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. *Stroke* 2003;34:392-396.

100. Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal PJ, Breteler MM, et al. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. *Stroke* 2003;34:1126-1129.

101. Greenberg SM, Vernooij MW, Cordonnier C, Viswanathan A, Al-Shahi Salman R, Warach S, et al. Cerebral microbleeds: a guide to detection and interpretation. *Lancet Neurol* 2009;8:165-174.

102. Martinez-Ramirez S, Greenberg SM, Viswanathan A. Cerebral microbleeds: histopathological correlation of neuroimaging. *Cerebrovasc Dis* 2011;32:528-534.

103. Shoamanesh A, Kwock CS, Benavente O. Cerebral microbleeds: histopathological correlation of neuroimaging. *Cerebrovasc Dis* 2011;32:528-534.

104. Viswanathan A, Chabriat H. Cerebral microhemorrhage. *Stroke* 2006;37:550-555.

105. Tsushima Y, Tanizaki Y, Aoki J, Endo K. MR detection of microhemorrhages in neurologically healthy adults. *Neuroradiology* 2002;44:31-36.

106. Poels MM, Vernooij MW, Ikram MA, Hofman A, Krestin GP, van der Lugt A, et al. Prevalence and risk factors of cerebral microbleeds: an update of the Rotterdam scan study. *Stroke* 2010;41:5103-5106.

107. Roob G, Schmidt R, Kapeller P, Lechner A, Hartung HP, Fazekas F. MRI evidence of past cerebral microbleeds in a healthy elderly population. *Neurology* 1999;52:991-994.

108. Dawber TR, Meadors GF, Moore FE Jr. Epidemiological approaches to heart disease: the Framingham Study. *Am J Public Health Nations Health* 1951;41:279-281.

109. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families. The Framingham offspring study. *J Am Epidem Biol* 1979;110:281-290.

110. Svinkeljongsdottir S, Sigurdsson S, Aspelund T, Kjartansson O, Eiriksdottir G, Valtsdottir B, et al. Cerebral microbleeds in the population based AGES-Reykjavik study: prevalence and location. *J Neurosurg Psychiatry* 2008;79:1002-1006.

111. Del Brutto VJ, Zambrano M, Mera RM, Del Brutto OH. Population-based study of cerebral microbleeds in stroke-free older adults living in rural Ecuador: The Atahualpa Project. *Stroke* 2015;46:1984-1986.
112. de Laat KF, van den Berg HA, van Norden AG, Gons RA, Olde Rikkert MG, de Leeuw FE. Microbleeds are independently related to gait disturbances in elderly individuals with cerebral small vessel disease. Stroke 2011;42:494–497.

113. Mitaki S, Nagai A, Oguro H, Yamaguchi S. Serum lipid fractions and cerebral microbleeds in a healthy Japanese population. Cerebrovasc Dis 2017;43:186–191.

114. Mok V, Srikanth V, Xiong Y, Phan TG, Moran C, Chu S, et al. Race-ethnicity and cerebral small vessel disease: comparison between Chinese and White populations. Int J Stroke 2014;9 Suppl A100:36–42.

115. Jeerakathil T, Wolf PA, Beiser A, Hald JK, Au R, Kase CS, et al. Cerebral microbleeds: prevalence and associations with cardiovascular risk factors in the Framingham Study. Stroke 2004;35:1831–1835.

116. Vernooij MW, van der Lugt A, Ikram MA, Wielopolski PA, Niessen WJ, Hofman A, et al. Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurology 2008;70:1208–1214.

117. Harris TB, Launer LJ, Eiriksdottir G, Kjartansson Q, Jonsson PV, Sigurdsson G, et al. Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. Am J Epidemiol 2007;165:1076–1087.

118. Akoudad S, Portegies ML, Koudstaal PJ, Hofman A, van der Lugt A, Ikram MA, et al. Cerebral microbleeds are associated with an increased risk of stroke: the Rotterdam Study. Circulation 2015;132:509–516.

119. Song TJ, Kim J, Kim YD, Nam HS, Lee HS, Nam CM, et al. The distribution of cerebral microbleeds determines their association with arterial stiffness in non-cardioembolic acute stroke patients. Eur J Neurol 2014;21:463–469.

120. Vernooij MW, Haag MD, van der Lugt A, Hofman A, Krestin GP, Stricker BH, et al. Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan Study. Arch Neural 2009;66:714–720.

121. Kakar P, Charidimou A, Werring DJ. Cerebral microbleeds: a new dilemma in stroke medicine. J RSM Cardiovasc Dis 2012;1:2048004012474754.

122. Altmann-Schneider I, Trompet S, de Craen AJ, van Es AC, Jukema JW, Stott DJ, et al. Cerebral microbleeds are predictive of mortality in the elderly. Stroke 2011;42:638–644.

123. van Es AC, van der Grond J, de Craen AJ, Westendorp RG, Bollen EL, Blauw GJ, et al. Cerebral microbleeds and cognitive functioning in the PROSPER study. Neurology 2011;77:1446–1452.

124. Choi P, Ren M, Phan TG, Callisaya M, Ly JV, Beare R, et al. Silent infarcts and cerebral microbleeds modify the associations of white matter lesions with gait and postural stability: population-based study. Stroke 2012;43:1505–1510.

125. Giu C, Cotch MF, Sigurdsson S, Jonsson PV, Jonsdottir MK, Sveinbjornsdottr S, et al. Cerebral microbleeds, retinopathy, and dementia: the AGES-Reykjavik Study. Neurology 2010;75:2221–2228.

126. Akoudad S, Wolters FJ, Viswanathan A, de Bruijn RF, van der Lugt A, Hofman A, et al. Association of cerebral microbleeds with cognitive decline and dementia. JAMA Neurol 2016;73:934–943.

127. Romero JR, Beiser A, Himali JJ, Shoamanesh A, DeCarli C, Seshadri S. Cerebral microbleeds and risk of incident dementia: the Framingham Heart Study. Neurobiol Aging 2017;54:94–99.

128. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Symposium: clearance of Aβ from the brain in Alzheimer’s disease: perivascular drainage of amyloid-β peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer’s disease. Brain Pathol 2008;18:253–266.

129. Charidimou A, Meegaahage R, Fox Z, Peeters A, Vandermeeren Y, Laloux P, et al. Enlarged perivascular spaces as a marker of underlying arteriopathy in intracerebral haemorrhage: a multicentre MRI cohort study. J Neurol Neurosurg Psychiatry 2013;84:624–629.

130. Martinez-Ramirez S, Pontes-Neto OM, Dumas AP, Auriel E, Halpin A, Quimby M, et al. Topography of dilated perivascular spaces in subjects from a memory clinic cohort. Neurology 2013;80:1551–1556.

131. Yakushiji Y, Charidimou A, Hara M, Noguchi T, Nishihara M, Eriguchi M, et al. Topography and associations of perivascular spaces in healthy adults: the Kashima scan study. Neurology 2014;83:2116–2123.

132. Zhu YC, Dufouil C, Mazoyer B, Soumaré A, Ricolfi F, Tzourio C, et al. Frequency and location of dilated Virchow-Robin spaces in elderly people: a population-based 3D MR imaging study. AJNR Am J Neuroradiol 2011;32:709–713.

133. Ramirez J, Bereczuk C, McNeely AA, Scott CJ, Gao F, Black SE. Visible Virchow-Robin spaces on magnetic resonance imaging of Alzheimer’s disease patients and normal elderly from the Sunnybrook Dementia Study. J Alzheimers Dis 2015;43:415–424.

134. Zhu YC, Tzourio C, Soumaré A, Mazoyer B, Dufouil C, Chabriat H. Severity of dilated Virchow–Robin spaces is associated with age, blood pressure, and MRI markers of small vessel disease: a population-based study. Stroke 2010;41:2483–2490.

135. Bokura H, Kobayashi S, Yamaguchi S. Distinguishing silent lacunar infarction from enlarged Virchow-Robin spaces: a magnetic resonance imaging and pathological study. J Neurol 1998;245:116–122.

136. Ding J, Sigurdsson S, Jonsson PV, Eiriksdottir G, Charidimou A,
Das et al. Asymptomatic Cerebral Small Vessel Disease

Cerebral microinfarcts: a systematic review of neuropathology and significance.

Lopez OL, et al. Large perivascular spaces visible on magnetic resonance imaging, cerebral small vessel disease progression, and risk of dementia: the Age, Gene/Environment Susceptibility-Reykjavik Study. JAMA Neurol 2017;74:1105-1112.

137. Maclullich AM, Wardlaw JM, Ferguson KJ, Starr JM, Seckl JR, Deary IJ. Enlarged perivascular spaces are associated with cognitive function in healthy elderly men. J Neurol Neurosurg Psychiatry 2004;75:1519-1523.

138. Patankar TF, Mitra D, Varma A, Snowden J, Neary D, Jackson A. Dilatation of the Virchow-Robin space is a sensitive indicator of cerebral microvascular disease: study in elderly patients with dementia. AJNR Am J Neuroradiol 2005;26:1512-1520.

139. Arba F, Quinn TJ, Hankey GJ, Lees KR, Wardlaw JM, Ali M, et al. Enlarged perivascular spaces and cognitive impairment after stroke and transient ischemic attack. Int J Stroke 2018;13:47-56.

140. Zhu YC, Dufouil C, Soumaré A, Mazoyer B, Chabriat H, Tzourio C. High degree of dilated Virchow-Robin spaces on MRI is associated with increased risk of dementia. J Alzheimers Dis 2010;22:663-672.

141. Vernooij MW, Ikram MA, Hofman A, Krestin GP, Breiteler MM, van der Lugt A. Superficial siderosis and microbleeds in cerebral amyloid angiopathy. Neurology 2009;73:202-205.

142. Charidimou A, Linn J, Vernooij MW, Opher C, Akoudad S, Baron JC, et al. Cortical superficial siderosis: detection and clinical significance in cerebral amyloid angiopathy and related conditions. Brain 2015;138:2126-2139.

143. Pichler M, Vemuri P, Rabinstein AA, Aakre J, Flemming KD, Brown RD Jr, et al. Prevalence and natural history of superficial siderosis: a population-based study. Stroke 2017;48:3210-3214.

144. Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Bovee BF, et al. The Mayo Clinic study of aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology 2008;30:58-69.

145. Shoamanesh A, Martínez-Ramírez S, Oliveira-Filho J, Reijmers Y, Falcone GJ, Ayres A, et al. Interrelationship of superficial siderosis and microbleeds in cerebral amyloid angiopathy. Neurology 2014;83:1838-1843.

146. Charidimou A, Martínez-Ramírez S, Shoamanesh A, Oliveira-Filho J, Frosch M, Vashkevich A, et al. Cerebral amyloid angiopathy with and without hemorrhage: evidence for different disease phenotypes. Neurology 2015;84:1206-1212.

147. Smith EE, Schneider JA, Wardlaw JM, Greenberg SM. Cerebral microinfarcts: the invisible lesions. Lancet Neurol 2012;11:272-282.

148. Brundel M, de Bresser J, van Dillen JJ, Kappelle LJ, Biessels GJ. Cerebral microinfarcts: a systematic review of neuropathological studies. J Cereb Blood Flow Metab 2012;32:425-436.

149. van Veluw SJ, Hilal S, Kuijf HJ, Ikram MK, Xin X, Yeow TB, et al. Cortical microinfarcts on 3T MRI: clinical correlates in memory-clinic patients. Alzheimers Dement 2015;11:1500-1509.

150. Hilal S, Sikkings E, Shaik MA, Chan QL, van Veluw SJ, Vrooman H, et al. Cortical cerebral microinfarcts on 3T MRI: a novel marker of cerebrovascular disease. Neurology 2016;87:1583-1590.

151. Jouvent E, Poupon C, Gray F, Paquet C, Mangin JF, Le Bihan D, et al. Intracortical infarcts in small vessel disease: a combined 7-T postmortem MRI and neuropathological case study in cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Stroke 2011;42:e27-e30.

152. van Veluw SJ, Zwanenburg JJ, Engelen-Lee J, Spliet WG, Hendriks J, Luijten PR, et al. In vivo detection of cerebral cortical microinfarcts with high–resolution 7T MRI. J Cereb Blood Flow Metab 2013;33:322-329.

153. van Veluw SJ, Heringa SM, Kuijf HJ, Koek HL, Luijten PR, Biessels GJ, et al. Cerebral cortical microinfarcts at 7 Tesla MRI in patients with early Alzheimer's disease. J Alzheimers Dis 2014;39:163-167.

154. van Dalen JW, Scurtic EE, van Veluw SJ, Caan MW, Nederveen AJ, Biessels GJ, et al. Cortical microinfarcts detected in vivo on 3 Tesla MRI: clinical and radiological correlates. Stroke 2015;46:255-257.

155. Wityk RJ. Cerebral cortical microinfarcts on 3-T magnetic resonance imaging: a new tool in the study of cerebrovascular ischemia. JAMA Neurol 2017;74:385-386.

156. Li Y, Maeda M, Kida H, Matsuo K, Shindo A, Taniguchi A, et al. In vivo detection of cortical microinfarcts on ultrahigh-field MRI. J Neuroimaging 2013;23:28-32.

157. van Rooden S, Goos JD, van Opstal AM, Versluis MJ, Webb AG, Blauw GJ, et al. Increased number of microinfarcts in Alzheimer disease at 7-T MR imaging. Radiology 2014;270:205-211.

158. Fu R, Wang Y, Wang Y, Liu L, Zhao X, Wang DZ, et al. The development of cortical microinfarcts is associated with intracranial atherosclerosis: data from the Chinese intracranial atherosclerosis study. J Stroke Cerebrovasc Dis 2015;24:2447-2454.

159. Longstreth WT Jr, Sonnen JA, Koepsell TD, Kukull WA, Larson EB, Montine TJ. Associations between microinfarcts and other macroscopic vascular findings on neuropathologic examination in 2 databases. Alzheimer Dis Assoc Disord 2009;23:291-294.

160. Wang LY, Larson EB, Sonnen JA, Shofer JB, McCormick W, Bowen JD, et al. Blood pressure and brain injury in older adults: findings from a community-based autopsy study. J...
Am Geriatr Soc 2009;57:1975–1981.

161. Troncoso JC, Zonderman AB, Resnick SM, Crain B, Pletnikova O, O'Brien RJ. Effect of infarcts on dementia in the Baltimore longitudinal study of aging. Ann Neurol 2008;64:168–176.

162. Hilal S, Chai YL, van Veluw S, Shaik MA, Ikram MK, Venkatesubramanian N, et al. Association between subclinical cardiac biomarkers and clinically manifest cardiac diseases with cortical cerebral microinfarcts. JAMA Neurol 2017;74:403–410.

163. Zheng L, Vinters HV, Mack WJ, Zarow C, Ellis WG, Chui HC. Cerebral atherosclerosis is associated with cystic infarcts and microinfarcts but not Alzheimer pathologic changes. Stroke 2013;44:2835–2841.

164. Rosman M, Zheng Y, Wong W, Lamoureux E, Saw SM, Tay WT, et al. Singapore Malay Eye Study: rationale and methodology of 6-year follow-up study (SIMES-2). Clin Exp Ophthalmol 2012;40:557–568.

165. Hilal S, Ikram MK, Saini M, Tan CS, Catindig JA, Dong YH, et al. Prevalence of cognitive impairment in Chinese: epidemiology of dementia in Singapore study. J Neurol Neurosurg Psychiatry 2013;84:686–692.

166. Brundel M, Reijmer YD, van Veluw SJ, Kuijf HJ, Luijten PR, Kappelle LJ, et al. Cerebral microvascular lesions on high-resolution 7-Tesla MRI in patients with type 2 diabetes. Diabetes 2014;63:3523–3529.

167. Pruzin JJ, Schneider JA, Capuano AW, Leurgans SE, Barnes LL, Ahima RS, et al. Diabetes, hemoglobin A1C, and regional Alzheimer disease and infarct pathology. Alzheimer Dis Assoc Disord 2017;31:41–47.

168. Yassi N, Hilal S, Lim YY, Salinas S, Kuijf H, Xia Y, et al. Cortical cerebral microinfarcts on 3T MRI in Alzheimer’s disease and mild cognitive impairment. Alzheimers Dement 2017;13(7 Suppl):P1378–P1379.

169. Arvanitakis Z, Leurgans SE, Barnes LL, Bennett DA, Schneider JA. Microinfarct pathology, dementia, and cognitive systems. Stroke 2011;42:722–727.

170. Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the unusual orders study. Curr Alzheimer Res 2012;9:628–645.

171. Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the rush Memory and Aging Project. Curr Alzheimer Res 2012;9:646–663.

172. Arvanitakis Z, Capuano AW, Leurgans SE, Buchman AS, Bennett DA, Schneider JA. The relationship of cerebral vessel pathology to brain microinfarcts. Brain Pathol 2017;27:77–85.

173. Smith EE, Saposnik G, Biessels GJ, Doublai FN, Fornage M, Gorelick PB, et al. Prevention of stroke in patients with silent cerebrovascular disease: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2017;48:e44–e71.

174. Staals J, Makin SD, Doublai FN, Dennis MS, Wardlaw JM. Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. Neurology 2014;83:1228–1234.

175. Cuadrado-Godía E, Dwivedi P, Sharma S, Olí Sanchez A, Roquer Gonzalez J, Balcells M, et al. Cerebral small vessel disease: a review focusing on pathophysiology, biomarkers, and machine learning strategies. J Stroke 2018;20:302–320.

176. Lau KK, Li L, Schulz U, Simoni M, Chan KH, Ho SL, et al. Total small vessel disease score and risk of recurrent stroke: validation in 2 large cohorts. Neurology 2017;88:2260–2267.

177. Poggesi A, Pasi M, Pescini F, Panton I, Inzitari D. Circulating biologic markers of endothelial dysfunction in cerebral small vessel disease: a review. J Cereb Blood Flow Metab 2016;36:72–94.

178. Gattringer T, Pinter D, Enzinger C, Seifert-Held T, Kneihsl M, Fandler S, et al. Serum neurofilament light is sensitive to active cerebral small vessel disease. Neurology 2017;89:2108–2114.

179. Duering M, Konieczny MJ, Tiedt S, Baykara E, Tuladhar AM, Leijser EV, et al. Serum neurofilament light chain levels are related to small vessel disease burden. J Stroke 2018;20:228–238.

180. Markus HS, Hunt B, Palmer K, Enzinger C, Schmidt H, Schmidt R. Markers of endothelial and haemostatic activation and progression of cerebral white matter hyperintensities: longitudinal results of the Austrian Stroke Prevention Study. Stroke 2005;36:1410–1414.

181. van Dijk EJ, Prins ND, Vermeer SE, Vroomen HA, Hofman A, Koudstaal PJ, et al. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation 2005;112:900–905.

182. Satizabal CL, Zhu YC, Mazoyer B, Dufouil C, Tzourio C. Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study. Neurology 2012;78:720–727.

183. Rizzi L, Marques FC, Rosset I, Moriguchi EH, Picon PD, Chaves ML, et al. C-reactive protein and cognition are unrelated to leukoaraiosis. ScientificWorldJournal 2014;2014:121679.

184. Schmidt R, Schmidt H, Pichler M, Enzinger C, Petrovic K, Nie derkorn K, et al. C-reactive protein, carotid atherosclerosis, and cerebral small-vessel disease: results of the Austrian Stroke Prevention Study. Stroke 2006;37:2910–2916.

185. Avcı AV, Lakadamyali H, Arikana S, Benli US, Kilinc M. High sensitivity C-reactive protein and cerebral white matter hyperintensities on magnetic resonance imaging in migraine patients. J Headache Pain 2015;16:9.

186. Ashjazadeh N, Fathi M, Shariat A. Evaluation of homocysteine level as a risk factor among patients with ischemic stroke and its subtypes. Iran J Med Sci 2013;38:233–239.

187. Dufouil C, de Kersaint-Gilly A, Besançon V, Levy C, Auffray E,
Brunnerneau L, et al. Longitudinal study of blood pressure and white matter hyperintensities: the EVA MRI cohort. *Neurology* 2001;56:921-926.

188. Fukuda H, Kitani M. Differences between treated and untreated hypertensive subjects in the extent of periventricular hyperintensities observed on brain MRI. *Stroke* 1995;26:1593-1597.

189. de Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hofman A, van Gijn J, et al. Hypertension and cerebral white matter lesions in a prospective cohort study. *Brain* 2002;125:765-772.

190. Firbank MJ, Wiseman RM, Burton EJ, Saxby BK, O’Brien JT, Ford GA. Brain atrophy and white matter hyperintensity change in older adults and relationship to blood pressure. Brain atrophy, WMH change and blood pressure. *J Neurol* 2007;254:713-721.

191. Dufouil C, Chalmers J, Coskun O, Besançon V, Bousser MG, Guillon P, et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. *Circulation* 2005;112:1644-1650.

192. Godin O, Tzourio C, Maillard P, Mazoyer B, Dufouil C. Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes: the Three-City (3C)-Dijon Magnetic Resonance Imaging Study. *Circulation* 2011;123:266-273.

193. van Middelaar T, Argiller TE, Schreuder FHBM, Deinum J, Richard E, Klijn CJM. Effect of antihypertensive medication on cerebral small vessel disease: a systematic review and meta-analysis. *Stroke* 2018;49:1531-1533.

194. Weber R, Weimar C, Blatchford J, Hermansson K, Wanke I, Möller-Hartmann C, et al. Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effective on cerebral infarcts and white matter lesions. *Neurology* 2005;64:1807-1809.

195. Bernick C, Katz R, Smith NL, Rapp S, Bhadelia R, Carlson M, et al. Statins and cognitive function in the elderly: the Cardiovascular Health Study. *Neurology* 2005;65:1388-1394.

196. Rha JH, Park HK, Park JJ, Yoo NY. Is antiplatelet treatment effective on the progression of white matter hyperintensities? 5 year follow up, propensity score adjusted, observational study. *Neurology* 2012;78(1 Suppl):P04.203.

197. Xiong Y, Wong A, Cavaliere M, Schmidt R, Chu WW, Liu X, et al. Prestroke statins, progression of white matter hyperintensities, and cognitive decline in stroke patients with confluent white matter hyperintensities. *Neurotherapeutics* 2014;11:606–611.

198. ten Dam VH, van den Heuvel DM, van Buchem MA, Westendorp RG, Bollen EL, Ford I, et al. Effect of pravastatin on cerebral infarcts and white matter lesions. *Neurology* 2005;64:1807–1809.

199. van Harten B, de Leeuw FE, Weinstein HC, Schelten P, Biessels GJ. Brain imaging in patients with diabetes: a systematic review. *Diabetes Care* 2006;29:2539–2548.

200. Torres ER, Strack EF, Fernandez CE, Tumey TA, Hitchcock ME. Physical activity and white matter hyperintensities: a systematic review of quantitative studies. *Prev Med Rep* 2015;2:319–325.

201. Yi Q, Jia Y, Wang J, Zhan X, Wang J, Wang Y. Antiplatelet therapy, cerebral microbleeds, and intracerebral hemorrhage: a meta-analysis. *Stroke* 2018;49:1751–1754.

202. Wobith M, Mayer C, Delbecq A, Gerstner A, Teepker M, et al. Predictors of new cerebral microbleeds in patients with cerebrovascular disease. *J Stroke Cerebrovasc Dis* 2016;25:1671–1677.

203. Charidimou A, Shoamanesh A, Al-Shahi Salman R, Cordonnier C, Perry LA, Sheth KN, et al. Cerebral amyloid angiopathy, cerebral microbleeds and implications for anticoagulation decisions: the need for a balanced approach. *Int J Stroke* 2018;13:117–120.